Literature DB >> 19051018

Treatment of HIV-associated diarrhea with curcumin.

Chris N Conteas1, Abraham M Panossian, Timothy T Tran, Hardeep M Singh.   

Abstract

Curcumin is the organic extract of turmeric and possesses known anti-inflammatory properties. Our aim was to explore the utility of curcumin in patients with HIV-associated diarrhea. Eight patients with HIV-associated diarrhea were given a mean daily dose of 1,862 mg of curcumin and followed for a mean of 41 weeks. All had resolution of diarrhea and normalization of stool quality in a mean time of 13 +/- 9.3 days. Mean number of bowel movements per day dropped from 7 +/- 3.6 to 1.7 +/- 0.5. Seven of eight patients had considerable weight gain on curcumin (10.8 +/- 8.9 lbs). Five of six patients had resolution of bloating and abdominal pain. Patients on anti-retroviral therapy experienced no discernible drug interactions, changes in CD(4) count, or changes in HIV viral load while taking curcumin. Curcumin therapy was associated with rapid and complete resolution of diarrhea, substantial weight gain, improvement in the reduction of bloating and abdominal pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19051018     DOI: 10.1007/s10620-008-0597-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  12 in total

1.  Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis.

Authors:  Marcia Cruz-Correa; Daniel A Shoskes; Patricia Sanchez; Rhongua Zhao; Linda M Hylind; Steven D Wexner; Francis M Giardiello
Journal:  Clin Gastroenterol Hepatol       Date:  2006-06-06       Impact factor: 11.382

Review 2.  AGA technical review: malnutrition and cachexia, chronic diarrhea, and hepatobiliary disease in patients with human immunodeficiency virus infection.

Authors:  C M Wilcox; L Rabeneck; S Friedman
Journal:  Gastroenterology       Date:  1996-12       Impact factor: 22.682

3.  Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV Cohort Study.

Authors:  R Weber; B Ledergerber; R Zbinden; M Altwegg; G E Pfyffer; M A Spycher; J Briner; L Kaiser; M Opravil; C Meyenberger; M Flepp
Journal:  Arch Intern Med       Date:  1999-07-12

Review 4.  [HIV enteropathy].

Authors:  L Beaugerie
Journal:  Ann Gastroenterol Hepatol (Paris)       Date:  1993 Jan-Feb

5.  Mechanisms of epithelial barrier impairment in HIV infection.

Authors:  M Stockmann; H Schmitz; M Fromm; W Schmidt; G Pauli; P Scholz; E O Riecken; J D Schulzke
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

6.  Supernatants of HIV-infected immune cells affect the barrier function of human HT-29/B6 intestinal epithelial cells.

Authors:  Heinz Schmitz; Katharina Rokos; Peter Florian; Alfred H Gitter; Michael Fromm; Peter Scholz; Reiner Ullrich; Martin Zeitz; Georg Pauli; Jörg-Dieter Schulzke
Journal:  AIDS       Date:  2002-05-03       Impact factor: 4.177

7.  Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.

Authors:  Hiroyuki Hanai; Takayuki Iida; Ken Takeuchi; Fumitoshi Watanabe; Yasuhiko Maruyama; Akira Andoh; Tomoyuki Tsujikawa; Yosihihide Fujiyama; Keiichi Mitsuyama; Michio Sata; Masami Yamada; Yasushi Iwaoka; Kazunari Kanke; Hideyuki Hiraishi; Kazuhisa Hirayama; Hajime Arai; Shigehito Yoshii; Masato Uchijima; Toshi Nagata; Yukio Koide
Journal:  Clin Gastroenterol Hepatol       Date:  2006-11-13       Impact factor: 11.382

8.  Gastrointestinal manifestations of the acquired immunodeficiency syndrome: a review of 22 cases.

Authors:  B Dworkin; G P Wormser; W S Rosenthal; S K Heier; M Braunstein; L Weiss; R Jankowski; D Levy; S Weiselberg
Journal:  Am J Gastroenterol       Date:  1985-10       Impact factor: 10.864

9.  Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.

Authors:  Jodie L Guest; Charnelda Ruffin; Jean M Tschampa; Kathryn E DeSilva; David Rimland
Journal:  Pharmacotherapy       Date:  2004-06       Impact factor: 4.705

10.  Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6.

Authors:  H Schmitz; M Fromm; C J Bentzel; P Scholz; K Detjen; J Mankertz; H Bode; H J Epple; E O Riecken; J D Schulzke
Journal:  J Cell Sci       Date:  1999-01       Impact factor: 5.285

View more
  5 in total

1.  Curcumin for the prevention of progression in monoclonal gammopathy of undetermined significance: A word of caution.

Authors:  A J M Vermorken; J Zhu; W J M VAN DE Ven; Y Cui; J P Fryns
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

Review 2.  Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral Therapy.

Authors:  Patrick G Clay; Rustin D Crutchley
Journal:  Infect Dis Ther       Date:  2014-11-12

Review 3.  Bioactive Effects of Curcumin in Human Immunodeficiency Virus Infection Along with the Most Effective Isolation Techniques and Type of Nanoformulations.

Authors:  Monica Butnariu; Cristina Quispe; Niranjan Koirala; Sujan Khadka; Carla Marina Salgado-Castillo; Muhammad Akram; Rabia Anum; Balakyz Yeskaliyeva; Natália Cruz-Martins; Miquel Martorell; Manoj Kumar; Radu Vasile Bagiu; Ahmad Faizal Abdull Razis; Usman Sunusi; Ramla Muhammad Kamal; Javad Sharifi-Rad
Journal:  Int J Nanomedicine       Date:  2022-08-15

4.  Diarrhoea Management using Over-the-counter Nutraceuticals in Daily practice (DIAMOND): a feasibility RCT on alternative therapy to reduce antibiotic use.

Authors:  Yanhong Jessika Hu; Xudong Zhou; Shanjuan Wang; Merlin Willcox; Colin Garner; David Brown; Taeko Becque; Beth Stuart; Zongru Han; Qin Chang; Michael Moore; Paul Little
Journal:  Pilot Feasibility Stud       Date:  2021-06-15

5.  Design, Synthesis, Anticancer Evaluation and Docking Studies of Novel Heterocyclic Derivatives Obtained via Reactions Involving Curcumin.

Authors:  Rita M Borik; Nagwa M Fawzy; Sherifa M Abu-Bakr; Magdy S Aly
Journal:  Molecules       Date:  2018-06-08       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.